Healthcare
Oryzon Genomics S.A.(ORYZF)
Live Price
Offline$3.65
+0.00% today
1Y Change
+13.20%
Window
Jun 25, 2025 β Jun 15, 2026
- Market Cap
- $220.00M
- Revenue Growth
- -100.0%
- EPS Growth
- +38.2%
- Dividend Yield
- 0.0%
Coverage: 246 bars Β· Jun 25, 2025 β Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Oryzon Genomics S.A. (ORYZF) is a Healthcare stock with a market cap of $220.00M and listed on OTC. The stock last traded around $3.65 and up 13.2% across the available one-year price window (Jun 25, 2025 β Jun 15, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +38.2%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +38.2%, free cash flow +82.0% with operating margin 0.0% and ROIC -3.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ORYZF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 18, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +38.2%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 18, 2026 | β | +9.3% | +10.8% | +9.1% |
2026 Feb 27, 2026 | +41.9% | +0.0% | -9.7% | -7.2% |
2025 Nov 7, 2025 | -1.0% | +0.0% | +0.0% | -6.9% |
Benchmark Edge
ORYZF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ORYZF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ORYZF Max Drawdown
-25.80%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ORYZF and SPY.
Company Overview
Oryzon Genomics S.A.
Other OTC
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in CornellΓ de Llobregat, Spain.
- Leadership
- Carlos Manuel Buesa Arjol
- IPO Date
- Dec 15, 2020
- Employees
- 47
- Street Address
- Sant Ferran 74
- Mailing
- CornellΓ de Llobregat, 08940
- Region
- CornellΓ de Llobregat, ES
- Reporting Currency
- USD
- Investor Line
- 34 93 515 13 13
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- β
- Price/Book
- 2.0
Growth
- Revenue
- -100.0%
- EPS
- +38.2%
- Free Cash Flow
- +82.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -2.6%
- ROIC
- -3.2%
Balance Sheet
- Debt/Equity
- 0.11
- Current Ratio
- 1.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.